<DOC>
	<DOCNO>NCT00539240</DOCNO>
	<brief_summary>The purpose project compare efficacy ( successful ) 1 ) standard-dose proton pump inhibitor ( PPI ) ( rabeprazole 20 mg daily ) ( medication completely block stomach produce acid ) plus low dose tricyclic antidepressant ( nortriptyline 50mg ) ( TCA ) ; 2 ) double-dose PPI ( rabeprazole 20 mg twice day ) ; 3 ) standard-dose PPI ( rabeprazole 20mg daily ) placebo ( inactive substance , like sugar pill ) determine relative symptom resolution health-related quality life gastroesophageal reflux disease ( disease characterize burn sensation ( heartburn ) behind breast bone cause backflow stomach content esophagus ) ( GERD ) patient fail standard-dose PPI randomly assign ( similar flip coin ) one three group .</brief_summary>
	<brief_title>Role Pain Modulation GERD Patients Who Failed Standard Dose PPI</brief_title>
	<detailed_description>Failure standard dose PPI control GERD symptom increasingly encounter clinical practice ( primary care sub-specialties ) become one challenging therapeutic dilemma GERD management . It estimate 30 % patient receive PPI daily continue report typical GERD symptom [ 1 ] . Presently , increase PPI dose standard care patient [ 2 ] . However , success relieve refractory GERD symptom therapeutic approach extremely limited , result frustration patient well health care provide . Furthermore , patient fail PPI continue seek medical attention may undergo variety invasive non-invasive test , thus consume already limited health care resource . Recent advancement understand diverse composition different GERD group well symptom generation lead recognition alteration pain perception important contribute factor PPI failure presence non-acid related stimulus others [ 3 ] . This study clarify first time role pain modulation patient fail standard dose PPI . The clinical experience double PPI dose , current standard care , limit relatively disappointing . Additionally , study may identify group PPI failure patient may benefit double dose PPI group benefit add pain modulator . This study timely , never perform address prevalent emerge clinical dilemma GI well primary care clinic .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Antidepressive Agents , Tricyclic</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Currently treat PPI , continue experience GERD symptom ( heartburn ) least 2 time per week . Known allergy intolerance TCA History serious arrhythmia use antiarrhythmic History seizures Subjects significant comorbidity , e.g. , cardiovascular , respiratory , urogenital , renal , gastrointestinal , hepatic , hematological , endocrine , neurologic psychiatric With evidence history drug abuse within past 6 month Erosive esophagitis , esophageal ulceration , peptic stricture , Barrett 's esophagus adenocarcinoma esophagus endoscopy History esophagogastric surgery Gastric duodenal lesion ( ulcer , tumor , etc . ) Women pregnant childbearing age contraception Patients unwilling unable provide inform consent Insulin dependent diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>acid reflux</keyword>
	<keyword>acid regurgitation</keyword>
	<keyword>esophagitis</keyword>
	<keyword>GERD</keyword>
	<keyword>heartburn</keyword>
	<keyword>pain</keyword>
	<keyword>peptic</keyword>
</DOC>